Healthcare provider profile · identity verified

Yujing Murray, MD

Family Practice · CANTON, MI · NPI 1750796736

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	431	138
Levothyroxine Sodium	Levothyroxine Sodium	260	88
Amlodipine Besylate	Amlodipine Besylate	224	89
Omeprazole	Omeprazole	206	80
Lisinopril	Lisinopril	204	63
Losartan Potassium	Losartan Potassium	170	56
Simvastatin	Simvastatin	150	42
Albuterol Sulfate Hfa	Albuterol Sulfate	149	46
Gabapentin	Gabapentin	128	50
Metoprolol Succinate	Metoprolol Succinate	124	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	117	41
Rosuvastatin Calcium	Rosuvastatin Calcium	113	44
Metformin Hcl	Metformin Hcl	108	40
Furosemide	Furosemide	102	36
Hydrochlorothiazide	Hydrochlorothiazide	102	33
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	89	34
Fluticasone Propionate	Fluticasone Propionate	84	31
Trazodone Hcl	Trazodone Hcl	84	31
Sertraline Hcl	Sertraline Hcl	72	29
Pantoprazole Sodium	Pantoprazole Sodium	68	20
Carvedilol	Carvedilol	65	29
Alendronate Sodium	Alendronate Sodium	64	29
Duloxetine Hcl	Duloxetine Hcl	64	26
Ibuprofen	Ibuprofen	64	22
Alprazolam	Alprazolam	63	28
Meloxicam	Meloxicam	59	24
Tamsulosin Hcl	Tamsulosin Hcl	59	17
Tramadol Hcl	Tramadol Hcl	59	30
Spironolactone	Spironolactone	58	25
Metoprolol Tartrate	Metoprolol Tartrate	57	20
Pravastatin Sodium	Pravastatin Sodium	57	26
Fluoxetine Hcl	Fluoxetine Hcl	56	17
Irbesartan	Irbesartan	52	21
Mounjaro	Tirzepatide	50	14
Glipizide Er	Glipizide	47	16
Eliquis	Apixaban	46	20
Metformin Hcl Er	Metformin Hcl	46	25
Famotidine	Famotidine	42	20
Montelukast Sodium	Montelukast Sodium	42	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	14
Lorazepam	Lorazepam	40	20
Clopidogrel	Clopidogrel Bisulfate	38	13
Amitriptyline Hcl	Amitriptyline Hcl	35	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	34	13
Oxycodone Hcl	Oxycodone Hcl	33	16
Ozempic	Semaglutide	33	14
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Pregabalin	Pregabalin	32	23
Escitalopram Oxalate	Escitalopram Oxalate	31	13
Jardiance	Empagliflozin	31	11
Zolpidem Tartrate	Zolpidem Tartrate	30	16
Atenolol	Atenolol	29	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	29	suppressed
Hydrocortisone	Hydrocortisone	29	suppressed
Lovastatin	Lovastatin	29	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	11
Bupropion Xl	Bupropion Hcl	28	15
Buspirone Hcl	Buspirone Hcl	28	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	12
Januvia	Sitagliptin Phosphate	27	suppressed
Ondansetron Odt	Ondansetron	27	15
Celecoxib	Celecoxib	25	14
Chlorthalidone	Chlorthalidone	25	suppressed
Prednisone	Prednisone	25	15
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	14
Diazepam	Diazepam	23	11
Azithromycin	Azithromycin	22	16
Finasteride	Finasteride	22	suppressed
Naproxen	Naproxen	22	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Clonazepam	Clonazepam	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Metformin Er Osmotic	Metformin Hcl	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	18
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Nitroglycerin	Nitroglycerin	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Potassium Chloride	Potassium Chloride	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Allopurinol	Allopurinol	16	suppressed
Topiramate	Topiramate	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Bumetanide	Bumetanide	15	suppressed
Cephalexin	Cephalexin	15	14
Fenofibrate	Fenofibrate	15	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Glyburide	Glyburide	15	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Ibandronate Sodium	Ibandronate Sodium	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Piroxicam	Piroxicam	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Felodipine Er	Felodipine	13	suppressed
Fluconazole	Fluconazole	13	11
Glimepiride	Glimepiride	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error